HER2 as a therapeutic target in gallbladder cancer—aye or nay?

Gallbladder cancer (GBC) is an uncommon cancer. Prevalence varies across different geographical locations with Chile having the highest incidence at 9.7 per 100,000 age-standardised rate followed by Bolivia and the Republic of Korea (South Korea) (1). Most patients present in advanced stages of the disease which is associated with a poor prognosis. Even with palliative chemotherapy, the median overall survival in advanced disease is less than 12 months (2,3). As such, the search for new therapeutic targets with the hope of improving survival in patients with this disease is much needed.